Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPE
Eyestem Research has secured approval from India's CDSCO to begin Phase 2 clinical trials for its Eyecyte-RPE cell therapy. This treatment aims to address geographic atrophy, a condition causing vision loss. The trials will assess the therapy's safety and effectiveness in a larger patient group.
.png)






.png)













.webp)

.webp)

%20(1).webp)

%20(1).webp)


.webp)



.webp)

.webp)

.webp)

%20(1).webp)

.webp)




